In a positive development, Zimbabwe has emerged as the first African country to authorise the use of the India's first indigenous COVID-19 vaccine, Covaxin, which has been developed by Hyderabad based Bharat Biotech in close collaboration with the Indian Council of Medical Research (ICMR) and Pune based National Institute of Virology, reports Times of India.
"Zimbabwe has authorized use of COVAXIN, India's indigenous COVID-19 vaccine, becoming the first country in Africa to do so. Trying to get it to Zimbabwe at an early date," Indian embassy in Zimbabwe said in a tweet on Thursday (4 March).
On Thursday, India's ambassador to Zimbabwe Vijay Khanduja called on the African country's Vice President Constantino Chiwenga.
"VP Chiwenga conveyed the good news of authorization of COVAXIN India's indigenous COVID-19 vaccine, in Zimbabwe," the Indian embassy said.
The development comes just days after President Jair Bolsonaro led Brazilian administration had secured a supply of 20 million doses of Covaxin which is a two-dose whole virion inactivated virus vaccine.
Meanwhile, Ukraine and France are also said to be engaged in talks with the Hyderabad based vaccine maker to secure dosages of the Covid-19 for inoculating their respective populations.
It should also be noted that Prime Minister (PM) Narendra Modi had also received the first shot of Covaxin on1 March at New Delhi based All India Institute of Medical Science (AIIMS) in the presence of institution's director Dr Randeep Guleria.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.
The embedded tweet could not be found…